强制仿制药处方的障碍

IF 0.4 Q4 PHARMACOLOGY & PHARMACY Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-07-01 DOI:10.4103/jpp.jpp_74_21
V. Virdi, Money Gupta, Rohit Gupta
{"title":"强制仿制药处方的障碍","authors":"V. Virdi, Money Gupta, Rohit Gupta","doi":"10.4103/jpp.jpp_74_21","DOIUrl":null,"url":null,"abstract":"Coronavirus pandemic has brought forth the urgency of providing affordable health care to everyone. Generic medicines are often one-fourth to one-tenth of the cost of the branded drugs, and so offer a remarkable opportunity to significantly lower the health-care expenditure. However, the argument for promoting generic medicines is indisputable, we have to think about the other enabling conditions which are necessary for a successful health policy on encouraging generics without causing unintended adverse repercussions. This paper attempts to answer such questions by considering the motivations of the various stakeholders of the broader health services ecosystem in India and undertaking a systematic analysis of the winners and losers from such a policy. We argue that generic prescription will not be successful without prior improvement in the state capacity for quality control of drug manufacturing; rise in awareness among the doctors, patients, and pharmacists; improved trust in the medical systems; and innovative demand-side interventions.","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":"12 1","pages":"115 - 119"},"PeriodicalIF":0.4000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hurdles in Mandatory Generic Medicine Prescription\",\"authors\":\"V. Virdi, Money Gupta, Rohit Gupta\",\"doi\":\"10.4103/jpp.jpp_74_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus pandemic has brought forth the urgency of providing affordable health care to everyone. Generic medicines are often one-fourth to one-tenth of the cost of the branded drugs, and so offer a remarkable opportunity to significantly lower the health-care expenditure. However, the argument for promoting generic medicines is indisputable, we have to think about the other enabling conditions which are necessary for a successful health policy on encouraging generics without causing unintended adverse repercussions. This paper attempts to answer such questions by considering the motivations of the various stakeholders of the broader health services ecosystem in India and undertaking a systematic analysis of the winners and losers from such a policy. We argue that generic prescription will not be successful without prior improvement in the state capacity for quality control of drug manufacturing; rise in awareness among the doctors, patients, and pharmacists; improved trust in the medical systems; and innovative demand-side interventions.\",\"PeriodicalId\":16761,\"journal\":{\"name\":\"Journal of Pharmacology & Pharmacotherapeutics\",\"volume\":\"12 1\",\"pages\":\"115 - 119\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacology & Pharmacotherapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jpp.jpp_74_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology & Pharmacotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jpp.jpp_74_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

冠状病毒大流行带来了为每个人提供负担得起的医疗保健的紧迫性。仿制药通常是品牌药物成本的四分之一到十分之一,因此为大幅降低医疗保健支出提供了一个绝佳的机会。然而,推广仿制药的论点是无可争议的,我们必须考虑其他有利条件,这些条件对于成功的鼓励仿制药而不造成意外不利影响的卫生政策是必要的。本文试图通过考虑印度更广泛的卫生服务生态系统的各个利益相关者的动机来回答这些问题,并对这一政策的赢家和输家进行系统分析。我们认为,如果不事先提高国家药品生产质量控制能力,非专利处方就不会成功;提高医生、病人和药剂师的认识;提高对医疗系统的信任;以及创新的需求侧干预措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Hurdles in Mandatory Generic Medicine Prescription
Coronavirus pandemic has brought forth the urgency of providing affordable health care to everyone. Generic medicines are often one-fourth to one-tenth of the cost of the branded drugs, and so offer a remarkable opportunity to significantly lower the health-care expenditure. However, the argument for promoting generic medicines is indisputable, we have to think about the other enabling conditions which are necessary for a successful health policy on encouraging generics without causing unintended adverse repercussions. This paper attempts to answer such questions by considering the motivations of the various stakeholders of the broader health services ecosystem in India and undertaking a systematic analysis of the winners and losers from such a policy. We argue that generic prescription will not be successful without prior improvement in the state capacity for quality control of drug manufacturing; rise in awareness among the doctors, patients, and pharmacists; improved trust in the medical systems; and innovative demand-side interventions.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
37
期刊最新文献
Allelic Variants in the Warfarin-related Genes VKORC1 and CYP2C9 in a Western Saudi Population N-Acetyl-l-Cysteine Ameliorations RenalFunction Early After Renal Ischemia and Reperfusion; it is not Protective over a LongTerm under a High-Sodium Diet in Rats Rationalization of Antibiotic Prescription: Modulation of the Gut Microbiome and Possibilities of Minimizing the Risks for the Development of Antibiotic Resistance—A Narrative Review The Science of Antioxidants: Balancing thePros and Cons for Our Health Use of Fixed-dose Combination Therapy with Remogliflozin and Vildagliptin as an Add-on Drug in Improving the Glycemic Control of Type 2 Diabetes Mellitus: An Observational Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1